

Amendments to the Claims

The listing of claims will replace all prior versions, and listings of claims in the application.

Claims 1 to 220: canceled.

221. (new) An isolated polypeptide comprising amino acids 1 to 214 of SEQ ID NO:2.

222. (new) The polypeptide of claim 221, wherein said polypeptide comprises amino acids -25 to 214 of SEQ ID NO:2.

223. (new) The polypeptide of claim 222, wherein said polypeptide comprises amino acids -26 to 214 of SEQ ID NO:2.

224. (new) The polypeptide of claim 221, which is produced by a recombinant host cell.

225. (new) The polypeptide of claim 224, wherein said recombinant host cell is a eukaryotic host cell.

226. (new) The polypeptide of claim 221, further comprising a heterologous polypeptide.

227. (new) The polypeptide of claim 226, wherein said heterologous polypeptide comprises an immunoglobulin Fc region.

228. (new) The polypeptide of claim 227, wherein said Fc region is a human immunoglobulin Fc region.

229. (new) A composition comprising the polypeptide of claim 221, and a carrier.

230. (new) The polypeptide of claim 221 wherein said polypeptide binds an antibody with specificity for a reference polypeptide consisting of amino acids 1 to 214 of SEQ ID NO:2.

231. (new) An isolated polypeptide comprising an amino acid sequence at least 90% identical to amino acids 1 to 214 of SEQ ID NO:2; wherein said polypeptide binds an antibody with specificity for a reference polypeptide consisting of amino acids 1 to 214 of SEQ ID NO:2.

232. (new) The polypeptide of claim 231, wherein the amino acid sequence is at least 95% identical to amino acids 1 to 214 of SEQ ID NO:2.

233. (new) The polypeptide of claim 231, which is produced by a recombinant host cell.

234. (new) The polypeptide of claim 233, wherein said recombinant host cell is a eukaryotic host cell.

235. (new) The polypeptide of claim 231, further comprising a heterologous polypeptide.

236. (new) The polypeptide of claim 235, wherein said heterologous polypeptide comprises an immunoglobulin Fc region.

237. (new) The polypeptide of claim 236, wherein said Fc region is a human immunoglobulin Fc region.

238. (new) A composition comprising the polypeptide of claim 231, and a carrier.

239. (new) An isolated polypeptide comprising an amino acid sequence at least 90% identical to amino acids -25 to 214 of SEQ ID NO:2; wherein said polypeptide binds an antibody with specificity for a reference polypeptide consisting of amino acids 1 to 214 of SEQ ID NO:2.

240. (new) The polypeptide of claim 239, wherein the amino acid sequence is at least 95% identical to a polypeptide comprising amino acids -25 to 214 of SEQ ID NO:2.

241. (new) The polypeptide of claim 239, which is produced by a recombinant host cell.

242. (new) The polypeptide of claim 241, wherein said recombinant host cell is a eukaryotic host cell.

243. (new) The polypeptide of claim 239, further comprising a heterologous polypeptide.

244. (new) The polypeptide of claim 243, wherein said heterologous polypeptide comprises an immunoglobulin Fc region.

245. (new) The polypeptide of claim 244, wherein said Fc region is a human immunoglobulin Fc region.

246. (new) A composition comprising the polypeptide of claim 239, and a carrier.

247. (new) An isolated polypeptide comprising an amino acid sequence at least 90% identical to amino acids -26 to 214 of SEQ ID NO:2; wherein said polypeptide binds an antibody with specificity for a reference polypeptide consisting of amino acids 1 to 214 of SEQ ID NO:2.

248. (new) The polypeptide of claim 247, wherein the amino acid sequence is at least 95% identical to a polypeptide comprising amino acids -26 to 214 of SEQ ID NO:2.

249. (new) The polypeptide of claim 247, which is produced by a recombinant host cell.

250. (new) The polypeptide of claim 249, wherein said recombinant host cell is a eukaryotic host cell.

251. (new) The polypeptide of claim 247, further comprising a heterologous polypeptide.

252. (new) The polypeptide of claim 251, wherein said heterologous polypeptide comprises an immunoglobulin Fc region.

253. (new) The polypeptide of claim 252, wherein said Fc region is a human immunoglobulin Fc region.

254. (new) A composition comprising the polypeptide of claim 247, and a carrier.

255. (new) An isolated polypeptide comprising the amino acid sequence of the soluble extracellular domain of TNFR5 (Tumor Necrosis Factor Receptor-5) encoded by the cDNA clone contained in ATCC Deposit No. 97788.

256. (new) The isolated polypeptide of claim 255, comprising the amino acid sequence of the soluble extracellular domain and the secretory leader sequence TNFR5 encoded by the cDNA clone contained in ATCC Deposit No. 97788.

257. (new) The polypeptide of claim 255, which is produced by a recombinant host cell.

258. (new) The polypeptide of claim 257, wherein said recombinant host cell is a eukaryotic host cell.

259. (new) The polypeptide of claim 255, further comprising a heterologous polypeptide.

260. (new) The polypeptide of claim 259, wherein said heterologous polypeptide comprises an immunoglobulin Fc region.

261. (new) The polypeptide of claim 260, wherein said Fc region is a human immunoglobulin Fc region

262. (new) A composition comprising the polypeptide of claim 259, and a carrier.

263. (new) The polypeptide of claim 259, wherein said polypeptide binds an antibody with specificity for a reference polypeptide consisting of amino acids 1 to 214 of SEQ ID NO:2.

264. (new) An isolated polypeptide comprising a first amino acid sequence at least 90% identical to a second amino acid sequence selected from the group consisting of:

- (a) amino acids m to 233 of SEQ ID NO:2, where m is an integer in the range of -26 to 27;
- (b) amino acids -26 to x of SEQ ID NO:2, where x is an integer in the range of 123 to 233; and
- (c) amino acids m to x of SEQ ID NO:2, m and x are defined in (a) and (b) above;

wherein said polypeptide binds an antibody with specificity for a reference polypeptide consisting of amino acids 1 to 233 of SEQ ID NO:2.

265. (new) The polypeptide of claim 264, wherein said second amino acid sequence is (a).

266. (new) The polypeptide of claim 265, wherein said first amino acid sequence is at least 95% identical to said second amino acid sequence.

267. (new) The polypeptide of claim 265, wherein the first amino acid sequence is (a).

268. (new) The polypeptide of claim 267, which comprises amino acids 27 to 233 of SEQ ID NO:2.

269. (new) The polypeptide of claim 264, wherein said second amino acid sequence is (b).

270. (new) The polypeptide of claim 269, wherein said first amino acid sequence is at least 95% identical to said second amino acid sequence.

271. (new) The polypeptide of claim 269, wherein the first amino acid sequence is (b).

272. (new) The polypeptide of claim 271 which comprises amino acids -26 to 123 of SEQ ID NO:2.

273. (new) The polypeptide of claim 264, wherein said second amino acid sequence is (c).

274. (new) The polypeptide of claim 273, wherein said first amino acid sequence is at least 95% identical to said second amino acid sequence.

275. (new) The polypeptide of claim 273, wherein said first amino acid sequence is (c).

276. (new) The polypeptide of claim 275, which comprises amino acids 27 to 123 of SEQ ID NO:2.

277. (new) The polypeptide of claim 264, which is produced by a recombinant host cell.

278. (new) The polypeptide of claim 277, wherein said recombinant host cell is a eukaryotic host cell.

279. (new) The polypeptide of claim 264, further comprising a heterologous polypeptide.

280. (new) The polypeptide of claim 279, wherein said heterologous polypeptide comprises an immunoglobulin Fc region.

281. (new) The polypeptide of claim 280, wherein said Fc region is a human immunoglobulin Fc region.

282. (new) A composition comprising the polypeptide of claim 264, and a carrier.